Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN

Immunology Letters

Volumn 162, Issue 1, 2014, Pages 87-93

  Mansourian, Mercedeh ^a   Badiee, Ali ^a,c   Jalali, Seyed Amir ^a,b   Shariat, Sheida ^a   Yazdani, Mona ^a   Amin, Mohamdreza ^a   Jaafari, Mahmoud Reza ^a,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Cationic liposome; CTL epitope; Fusogenic liposome; HER2 neu peptide; Peptide vaccine

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; CPG OLIGODEOXYNUCLEOTIDE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTAMYLLYSYLALANYLALANYLTRYPTOPHANYLCYSTEINYLARGINYLTRYPTOPHANYLGLYCYLPHENYLALANYLLYSYLLYSYLARGINYLLYSYLLYSYLPROLYLPROLYLGLYCYLISOLEUCYLALANYLGLYCINE; LIPOSOME; PEPTIDE VACCINE; UNCLASSIFIED DRUG; UREA; 1,2-DIOLEOYLOXY-3-(TRIMETHYLAMMONIUM)PROPANE; CANCER VACCINE; CPG-OLIGONUCLEOTIDE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; MONOUNSATURATED FATTY ACID; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE FRAGMENT; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; ENCAPSULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; SURVIVAL; TUMOR CELL; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; DISEASE MODEL; HUMAN; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MORTALITY; NEOPLASMS; PATHOLOGY; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; IMMUNIZATION; LIPOSOMES; MICE; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTOR, ERBB-2; SPLEEN; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN;

EID: 84908308856     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.07.008     Document Type: Article

References (37)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Curigliano G., Spitaleri G., Pietri E., Rescigno M., de Braud F., Cardillo A., et al. Breast cancer vaccines: a clinical reality or fairy tale. Ann Oncol 2006, 17:750-762.
3. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl. 2):1-13.
4. Emens L.A., Reilly R.T., Jaffee E.M. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 2005, 12:1-17.
5. Ladjemi M.Z., Jacot W., Chardes T., Pelegrin A., Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010, 59:1295-1312.
6. Berzofsky J.A., Oh S., Terabe M. Peptide vaccines against cancer. Cancer Treat Res 2005, 123:115-136.
7. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96:3102-3108.
8. Salazar L.G., Fikes J., Southwood S., Ishioka G., Knutson K.L., Gooley T.A., et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003, 9:5559-5565.
9. Wang C., Zhuang Y., Zhang Y., Luo Z., Gao N., Li P., et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 2012, 30:4790-4799.
10. Tartour E., Ciree A., Haicheur N., Benchetrit F., Fridman W.H. Development of non-live vectors and procedures (liposomes, pseudo-viral particles, toxin, beads, adjuvants. . .) as tools for cancer vaccines. Immunol Lett 2000, 74:45-50.
11. Firouzmand H., Badiee A., Khamesipour A., Heravi Shargh V., Alavizadeh S.H., Abbasi A., et al. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Trop 2013, 128:528-535.
12. Shargh V.H., Jaafari M.R., Khamesipour A., Jaafari I., Jalali S.A., Abbasi A., et al. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine 2012, 30:3957-3964.
13. Henriksen-Lacey M., Christensen D., Bramwell V.W., Lindenstrøm T., Agger E.M., Andersen P., et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release 2010, 145:102-108.
14. Christensen D., Korsholm K.S., Andersen P., Agger E.M. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2011, 10:513-521.
15. Yan W., Chen W., Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 2007, 44:3672-3681.
16. Jalali S.A., Sankian M., Tavakkol-Afshari J., Jaafari M.R. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD nanoparticles. Nanomed Nanotechnol Biol Med 2012, 8:692-701.
17. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006, 117:78-88.
18. Lochmann D., Weyermann J., Georgens C., Prassl R., Zimmer A. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1. Physicochemical characterization. Eur J Pharm Biopharm 2005, 59:419-429.
19. Mochizuki S., Kanegae N., Nishina K., Kamikawa Y., Koiwai K., Masunaga H., et al. The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine. Biochim Biophys Acta 2013, 1828:412-418.
20. Koshkaryev A., Piroyan A., Torchilin V.P. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett 2013, 334:293-301.
21. Farhood H., Serbina N., Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1995, 1235:289-295.
22. Lonsdorf A.S., Kuekrek H., Stern B.V., Boehm B.O., Lehmann P.V., Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003, 171:3941-3946.
23. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003, 63:3281-3288.
24. Riviere K., Kieler-Ferguson H.M., Jerger K., Szoka F.C. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. J Control Release 2011, 153:288-296.
25. Wang C.H., Huang Y.Y. Encapsulating protein into preformed liposomes by ethanol-destabilized method. Artif Cells Blood Substit Immobil Biotechnol 2003, 31:303-312.
26. Huang Z., Jaafari M.R., Szoka F.C. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew Chem Int Ed Engl 2009, 48:4146-4149.
27. Canchi D.R., Garcia A.E. Cosolvent effects on protein stability. Annu Rev Phys Chem 2013, 64:273-293.
28. Kuramoto Y., Nishikawa M., Hyoudou K., Yamashita F., Hashida M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release 2006, 115:226-233.
29. Herbáth M., Szekeres Z., Kövesdi D., Papp K., Erdei A., Prechl J. Coadministration of antigen-conjugated and free CpG: effects of in vitro and in vivo interactions in a murine model. Immunol Lett 2014, 160:178-185.
30. Li W.M., Dragowska W.H., Bally M.B., Schutze-Redelmeier M.-P. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003, 21:3319-3329.
31. Brgles M., Habjanec L., Halassy B., Tomašić J. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. Vaccine 2009, 27:5435-5442.
32. Andreasson K., Eriksson M., Tegerstedt K., Ramqvist T., Dalianis T. CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles. PLoS ONE 2010, 5:e11580.
33. Muranski P., Restifo N.P. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009, 21:200-208.
34. Kmieciak M., Worschech A., Nikizad H., Gowda M., Habibi M., Depcrynski A., et al. CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat 2011, 126:385-394.
35. Perez-Diez A., Joncker N.T., Choi K., Chan W.F., Anderson C.C., Lantz O., et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109:5346-5354.
36. Qin Z., Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000, 12:677-686.
37. Wang R.-F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001, 22:269-276.